Alamar Biosciences reports Q3 profit surge and lifts full‑year revenue outlook
Alamar Biosciences announced third‑quarter 2026 revenue of $33.5 million, up roughly 65%‑68% year‑over‑year, driven by a sharp rise in consumables sales. Net loss widened to $13.3 million, while gross margin improved to 61.5%. The company raised its full‑year 2026 revenue guidance to $121 million‑$123 million and highlighted new partnerships with UK Biobank and GSK.
Why it matters
The higher guidance signals stronger demand for Alamar’s NULISA platform, which could boost future sales and cash flow, while the widened loss reflects higher operating expenses that investors will monitor. The new collaborations may expand the company’s addressable market and provide additional revenue streams.
Key facts
- 1Q3 2026 revenue was $33.5 million, up 68% YoY. investing.com
- 2Net loss for the quarter was $13.3 million, or $0.19 per share. investing.com
- 3Gross margin expanded to 61.5% from 59.7% a year earlier. investing.com
- 4Full‑year 2026 revenue guidance was raised to $121 million‑$123 million. finance.yahoo.com
- 5Biopharma customers accounted for 49% of Q3 revenue, up from 42% in the prior quarter. finance.yahoo.com
- 6Cash and short‑term investments totaled $231.5 million as of September 30, 2026. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.